QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
NYSEAMERICAN:CANF

Can-Fite BioPharma (CANF) Stock Forecast, Price & News

$2.91
+0.12 (+4.30%)
(As of 06/5/2023 ET)
Compare
Today's Range
$2.87
▼
$2.97
50-Day Range
$1.64
▼
$2.80
52-Week Range
$1.52
▼
$11.20
Volume
31,100 shs
Average Volume
73,919 shs
Market Capitalization
$10.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Can-Fite BioPharma MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Can-Fite BioPharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.03) to ($5.12) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.82 out of 5 stars

See Top Rated MarketRank™ Stocks Here

CANF stock logo

About Can-Fite BioPharma (NYSEAMERICAN:CANF) Stock

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

Receive CANF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CANF Stock News Headlines

June 2, 2023 | finance.yahoo.com
Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
June 1, 2023 | finance.yahoo.com
Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
June 5, 2023 | Behind the Markets (Ad)
BREAKING: The truth about war with China
Foreign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.
May 30, 2023 | finance.yahoo.com
Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
May 29, 2023 | americanbankingnews.com
Can-Fite BioPharma (NYSE:CANF) Research Coverage Started at StockNews.com
May 27, 2023 | americanbankingnews.com
StockNews.com Initiates Coverage on Can-Fite BioPharma (NYSEAMERICAN:CANF)
May 18, 2023 | americanbankingnews.com
Can-Fite BioPharma (NYSEAMERICAN:CANF) Stock Price Crosses Below 50 Day Moving Average of $2.70
May 15, 2023 | benzinga.com
Can-Fite: Presenting Namodenoson's New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
June 5, 2023 | Behind the Markets (Ad)
BREAKING: The truth about war with China
Foreign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.
May 15, 2023 | finance.yahoo.com
Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
May 11, 2023 | markets.businessinsider.com
Pre-market Movers: GFAI, SONO, KLXE, CDNA, DMRC…
May 11, 2023 | americanbankingnews.com
Can-Fite BioPharma (NYSEAMERICAN:CANF) Now Covered by StockNews.com
May 10, 2023 | finance.yahoo.com
All You Need to Know About Can-Fite Biopharma Ltd (CANF) Rating Upgrade to Buy
May 9, 2023 | americanbankingnews.com
Can-Fite BioPharma (NYSE:CANF) Receives New Coverage from Analysts at StockNews.com
May 2, 2023 | finance.yahoo.com
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
April 26, 2023 | finanznachrichten.de
CAN-FITE BIOPHARMA LTD ADR
April 24, 2023 | finance.yahoo.com
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
April 10, 2023 | markets.businessinsider.com
Can-Fite: CHMP Issues Positive Opinion On Piclidenoson Phase III Clinical Trial
April 10, 2023 | finance.yahoo.com
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
April 3, 2023 | americanbankingnews.com
Can-Fite BioPharma (NYSE:CANF) Rating Increased to Hold at StockNews.com
April 1, 2023 | americanbankingnews.com
Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) Sees Significant Growth in Short Interest
March 30, 2023 | benzinga.com
Can-Fite BioPharma Clocks 4.7% YoY Revenue Decline In FY22 To $0.81M
March 30, 2023 | finance.yahoo.com
Can-Fite Reports 2022 Financial Results & Provides Clinical Update
March 25, 2023 | americanbankingnews.com
Can-Fite BioPharma (NYSE:CANF) Downgraded by StockNews.com to "Sell"
March 16, 2023 | finance.yahoo.com
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
March 15, 2023 | benzinga.com
Can Fite Biofarma Stock (AMEX:CANF), Guidance and Forecast
March 13, 2023 | finance.yahoo.com
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
See More Headlines

CANF Price History

CANF Company Calendar

Last Earnings
3/30/2023
Today
6/05/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:CANF
CUSIP
N/A
CIK
1536196
Web
www.canfite.co.il
Phone
(723) 924-1114
Fax
972-3924-9378
Employees
8
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($3.71)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,170,000.00
Net Margins
-1,255.93%
Pretax Margin
-1,255.93%
Return on Equity
-120.33%
Return on Assets
-74.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.66
Quick Ratio
3.66

Sales & Book Value

Annual Sales
$810,000.00
Price / Sales
12.72
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.33 per share
Price / Book
2.19

Miscellaneous

Outstanding Shares
3,540,000
Free Float
3,512,000
Market Cap
$10.30 million
Optionable
Optionable
Beta
1.29

Key Executives

  • Pnina Fishman
    Chief Executive Officer & Director
  • Motti Farbstein
    Chief Financial & Operating Officer
  • Zivit Harpaz
    Director-Regulatory & Clinical Operations
  • Michael Silverman
    Medical Director
  • Sari Fishman
    Vice President-Business Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













CANF Stock - Frequently Asked Questions

Should I buy or sell Can-Fite BioPharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Can-Fite BioPharma in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CANF shares.
View CANF analyst ratings or view top-rated stocks.

How have CANF shares performed in 2023?

Can-Fite BioPharma's stock was trading at $0.6130 at the start of the year. Since then, CANF shares have increased by 374.7% and is now trading at $2.91.
View the best growth stocks for 2023 here.

Are investors shorting Can-Fite BioPharma?

Can-Fite BioPharma saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 93,300 shares, an increase of 311.0% from the April 30th total of 22,700 shares. Based on an average trading volume of 57,700 shares, the short-interest ratio is presently 1.6 days.
View Can-Fite BioPharma's Short Interest.

How were Can-Fite BioPharma's earnings last quarter?

Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) issued its quarterly earnings results on Thursday, March, 30th. The biotechnology company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.54. The biotechnology company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.50 million. Can-Fite BioPharma had a negative net margin of 1,255.93% and a negative trailing twelve-month return on equity of 120.33%.

When did Can-Fite BioPharma's stock split?

Can-Fite BioPharma shares reverse split on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Can-Fite BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Can-Fite BioPharma investors own include OPKO Health (OPK), Advanced Micro Devices (AMD), BioLineRx (BLRX), Genocea Biosciences (GNCA), Arbutus Biopharma (ABUS), Biocept (BIOC), Pfizer (PFE), Protalix BioTherapeutics (PLX), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

What is Can-Fite BioPharma's stock symbol?

Can-Fite BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CANF."

Who are Can-Fite BioPharma's major shareholders?

Can-Fite BioPharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.32%).

How do I buy shares of Can-Fite BioPharma?

Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Can-Fite BioPharma's stock price today?

One share of CANF stock can currently be purchased for approximately $2.91.

How much money does Can-Fite BioPharma make?

Can-Fite BioPharma (NYSEAMERICAN:CANF) has a market capitalization of $10.30 million and generates $810,000.00 in revenue each year. The biotechnology company earns $-10,170,000.00 in net income (profit) each year or ($3.71) on an earnings per share basis.

How can I contact Can-Fite BioPharma?

Can-Fite BioPharma's mailing address is 10 Bareket Street, Kiryat Matalon P.O. Box 7537, PETAH TIKVA, 49170, Israel. The official website for the company is www.canfite.co.il. The biotechnology company can be reached via phone at (723) 924-1114, via email at info@canfite.co.il, or via fax at 972-3924-9378.

This page (NYSEAMERICAN:CANF) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -